详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Huaxi MR Research Center (HMRRC), Department of Radiology, Functional and Molecular Imaging Key Laboratory ofSichuan Province, West China Hospital, Sichuan University, Chengdu, China, [2]Department of Clinic Medical Center,Dazhou Central Hospital, Dazhou, China, [3]Department of Radiology, School of Medicine, Stanford University, Stanford,CA, United States, [4]Department of Biomedical Engineering, Institute for Quantitative Health Science and Engineering (IQ),Michigan State University, East Lansing, MI, United States

出处：

DOI：

摘要：

For colorectal cancer patients, traditional biomarker deficient mismatch repair/microsatellite instability (dMMR/MSI) is an accurate predictor of immune checkpoint inhibitors (ICIs). Recent years, researchers considered tumor mutation burden (TMB) as another predictive biomarker which means the number of nonsynonymous mutations in cancer cells. Several studies have proven that TMB can evaluate the efficacy of ICI therapy in diverse types of cancer, especially in non-small cell lung cancer and melanoma. However, studies on the association between TMB and the response to ICI therapy in colorectal cancer alone are still lacking. In this study, we aim to verify the effect of TMB as a biomarker in predicting the efficacy of ICIs in colorectal cancer.We searched the PubMed and Ovid MEDLINE databases up to May 1, 2021 and screened studies for eligibility. Thirteen studies published from 2015 to 2021 with 5062 patients were included finally. We extracted and calculated hazard ratios (HRs) and odds ratios (ORs) of overall survival (OS) and objective response rates (ORRs) and their 95% confidence intervals (95% CIs). Pooled HR and OR were evaluated to compare OS and ORR between TMB-high and TMB-low groups in colorectal cancer patients. Meanwhile, we assessed heterogeneity with the I 2 statistic and p-values and performed publication bias assessments, sensitivity analyses, and subgroup analyses to search the cause of heterogeneity.The TMB-high patient group had a longer OS than the TMB-low patient group (HR = 0.68, 95% CI: 0.51, 0.92, p = 0.013) among colorectal cancer patients receiving ICIs. In addition, the TMB-high patient group was superior in terms of ORR (OR = 19.25, 95% CI: 10.06, 36.82, p < 0.001) compared to the TMB-low patient group.In conclusion, this meta-analysis revealed that TMB can be used as a potential predictive biomarker of colorectal cancer patients receiving ICI therapy. Nevertheless, this finding is not stable enough. Therefore, many more randomized controlled trials are needed to prove that TMB is reliable enough to be used clinically to predict the efficacy of immunotherapy in colorectal cancer. And the most relevant biomarker remains to be determined when TMB high overlaps with other biomarkers like MSI and TILs.Copyright © 2021 Li, Ma, Wu, Zeng, Song, Zhang, Li, Lui and Wu.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 2 区

医学

小类 | 2 区免疫学

最新[2023]版：

大类 | 2 区医学

小类 | 2 区免疫学

第一作者：

第一作者机构： [1]Huaxi MR Research Center (HMRRC), Department of Radiology, Functional and Molecular Imaging Key Laboratory ofSichuan Province, West China Hospital, Sichuan University, Chengdu, China,

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：